RA Capital Management, L.P. and related parties report a 9.99% beneficial stake in Geron Corporation as of June 30, 2026. Through RA Capital Healthcare Fund, L.P., they report beneficial ownership of 66,502,728 shares of common stock, including 42,809,751 shares held directly and Pre-Funded Warrants.
The Fund holds Pre-Funded Warrants exercisable for up to 29,053,145 additional shares, but a Beneficial Ownership Blocker prevents exercises that would push ownership above 9.99%. The 9.99% figure is calculated using 642,000,000 shares outstanding plus 23,692,977 shares issuable upon warrant exercise; EDGAR cover page percentages are rounded down to 9.9%. RA Capital, Peter Kolchinsky, and Rajeev Shah disclaim beneficial ownership except for Section 13(d) purposes.
Positive
None.
Negative
None.
Key Figures
Beneficially owned shares:66,502,728 sharesOwnership percentage:9.99%Directly held common shares:42,809,751 shares+3 more
6 metrics
Beneficially owned shares66,502,728 sharesGeron common stock beneficially owned by each Reporting Person as of June 30, 2026
Ownership percentage9.99%Beneficial ownership of Geron common stock as of June 30, 2026 before EDGAR rounding to 9.9%
Directly held common shares42,809,751 sharesGeron common stock directly held by RA Capital Healthcare Fund, L.P.
Pre-Funded Warrants capacity29,053,145 sharesShares of Geron common stock exercisable under Pre-Funded Warrants held by the Fund
Shares used in ownership calculation642,000,000 sharesGeron common stock outstanding as of June 30, 2026, used to compute ownership percentage
Warrant shares in percentage base23,692,977 sharesGeron shares issuable upon exercise of Pre-Funded Warrants included in the 9.99% calculation
Key Terms
Pre-Funded Warrants, Beneficial Ownership Blocker, Section 13(d) of the Act, beneficially owned, +1 more
5 terms
Pre-Funded Warrantsfinancial
"The Fund directly holds 42,809,751 shares of common stock and pre-funded warrants"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Beneficial Ownership Blockerfinancial
"The Pre-Funded Warrants contain a provision (the "Beneficial Ownership Blocker")"
A beneficial ownership blocker is a legal or structural device that prevents a shareholder from being treated as the ultimate owner of enough shares to trigger control, reporting, or voting thresholds. Think of it like a speed bump that stops an investor from reaching a stake size that would force corporate disclosure or change control rights. Investors care because it affects who controls the company, how shares vote, regulatory filings, takeover risk and therefore potential value or liquidity of their holdings.
Section 13(d) of the Actregulatory
"may be deemed a beneficial owner, for purposes of Section 13(d) of the Act"
beneficially ownedfinancial
"sets forth the aggregate number of shares of common stock of the Issuer beneficially owned"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
disclaim beneficial ownershipregulatory
"RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities"
FAQ
What percentage of Geron (GERN) does RA Capital report owning?
RA Capital and related reporting persons state beneficial ownership of 9.99% of Geron’s common stock as of June 30, 2026, calculated using 642,000,000 shares outstanding plus 23,692,977 shares issuable upon exercise of Pre-Funded Warrants.
How many Geron (GERN) shares does RA Capital’s fund beneficially own?
RA Capital Healthcare Fund, L.P. reports beneficial ownership of 66,502,728 Geron common shares as of June 30, 2026, including 42,809,751 shares held directly and additional shares underlying Pre-Funded Warrants, subject to a Beneficial Ownership Blocker.
What are the terms of RA Capital’s Pre-Funded Warrants in Geron (GERN)?
The Fund holds Pre-Funded Warrants exercisable for up to 29,053,145 Geron shares. A 9.99% Beneficial Ownership Blocker restricts exercises that would raise combined ownership above this level, currently limiting beneficial ownership to 66,502,728 shares.
How was RA Capital’s 9.99% Geron (GERN) ownership percentage calculated?
The 9.99% figure is based on 642,000,000 Geron shares outstanding as of June 30, 2026 plus 23,692,977 shares issuable upon warrant exercise. Due to EDGAR limits, the cover page shows a rounded-down 9.9% value.
Do RA Capital, Peter Kolchinsky, and Rajeev Shah claim full beneficial ownership of their Geron (GERN) position?
They state they may be deemed beneficial owners under Section 13(d) but explicitly disclaim beneficial ownership of the reported securities, except for purposes of determining their Section 13(d) obligations.
Who controls voting and investment power over RA Capital’s Geron (GERN) holdings?
RA Capital serves as investment adviser to the Fund and holds the sole power to vote and dispose of the Geron securities in the Fund’s portfolio. The Fund has delegated this authority and disclaims beneficial ownership for Section 13(d) purposes.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 6)
GERON CORPORATION
(Name of Issuer)
Common Stock, $0.001 par value per share
(Title of Class of Securities)
374163103
(CUSIP Number)
06/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
374163103
1
Names of Reporting Persons
RA Capital Management, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
66,502,728.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
66,502,728.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
66,502,728.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
IA, PN
SCHEDULE 13G
CUSIP Number(s):
374163103
1
Names of Reporting Persons
Peter Kolchinsky
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
66,502,728.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
66,502,728.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
66,502,728.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
CUSIP Number(s):
374163103
1
Names of Reporting Persons
Rajeev Shah
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
66,502,728.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
66,502,728.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
66,502,728.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
CUSIP Number(s):
374163103
1
Names of Reporting Persons
RA Capital Healthcare Fund, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
66,502,728.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
66,502,728.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
66,502,728.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
GERON CORPORATION
(b)
Address of issuer's principal executive offices:
919 East Hillsdale Boulevard, Suite 250, Foster City, CA, 94404.
Item 2.
(a)
Name of person filing:
The names of the persons filing this report (collectively, the "Reporting Persons") are:
RA Capital Management, L.P. ("RA Capital")
Peter Kolchinsky
Rajeev Shah
RA Capital Healthcare Fund, L.P. (the "Fund")
The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G/A.
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of each of the Reporting Persons is:
c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston MA 02116
(c)
Citizenship:
RA Capital and the Fund are Delaware limited partnerships.
Dr. Kolchinsky and Mr. Shah are United States citizens.
(d)
Title of class of securities:
Common Stock, $0.001 par value per share
(e)
CUSIP No.:
374163103
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Row 9 of each Reporting Person's cover page to this Schedule 13G/A sets forth the aggregate number of shares of common stock of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference.
The Fund directly holds 42,809,751 shares of common stock and pre-funded warrants ("Pre-Funded Warrants") exercisable for up to 29,053,145 shares of common stock. The Pre-Funded Warrants contain a provision (the "Beneficial Ownership Blocker"), which precludes the exercise of the Pre-Funded Warrants to the extent that, following exercise, the Fund, together with its affiliates and other attribution parties, would own more than 9.99% of the common stock outstanding. The Fund is currently prohibited from exercising a portion of the Pre-Funded Warrants to the extent that such exercise would result in beneficial ownership of more than 66,502,728 shares of common stock.
RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and may be deemed a beneficial owner, for purposes of Section 13(d) of the Act, of any securities of the Issuer held by the Fund. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund's portfolio, including the shares of the Issuer's common stock reported herein. Because the Fund has divested voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days' notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G/A other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13G/A shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.
(b)
Percent of class:
Due to the Beneficial Ownership Blocker listed in the Pre-Funded Warrants, each Reporting Person's beneficial ownership percentage was 9.99% as of June 30, 2026. Such percentage is based upon the sum of (i) 642,000,000 shares of the Issuer's common stock outstanding as of June 30, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on August 5, 2026 and (ii) 23,692,977 shares of common stock issuable upon the exercise of the Pre-Funded Warrants. Due to field limitations of the EDGAR filing system, the percentages listed in row 11 of the Reporting Persons' cover pages have been rounded down to 9.9%.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference.
(ii) Shared power to vote or to direct the vote:
Row 6 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference.
(iii) Sole power to dispose or to direct the disposition of:
Row 7 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference.
(iv) Shared power to dispose or to direct the disposition of:
Row 8 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
RA Capital Management, L.P.
Signature:
/s/ Peter Kolchinsky
Name/Title:
By Peter Kolchinsky, Authorized Signatory
Date:
08/14/2026
Peter Kolchinsky
Signature:
/s/ Peter Kolchinsky
Name/Title:
Peter Kolchinsky
Date:
08/14/2026
Rajeev Shah
Signature:
/s/ Rajeev Shah
Name/Title:
Rajeev Shah
Date:
08/14/2026
RA Capital Healthcare Fund, L.P.
Signature:
/s/ Peter Kolchinsky
Name/Title:
By RA Capital Healthcare Fund GP, LLC, its General Partner, By Peter Kolchinsky, Manager
Date:
08/14/2026
Exhibit Information
Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to Schedule 13G/A filed on May 15, 2025)